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ABSTRACT
Introduction: The glucagon-like peptide-1
receptor agonists liraglutide and lixisenatide are
effective at reducing glycated hemoglobin
(HbA1c) levels in patients with type 2 diabetes
mellitus (T2DM). Although liraglutide has
demonstrated superior efficacy in head-to-head
clinical trials, real-world evidence of compara-
tive effectiveness is lacking. This observational
study aimed to assess the effectiveness of
liraglutide versus lixisenatide in UK clinical
practice.
Methods: Electronic medical records from The
Health Improvement Network (THIN) UK pri-
mary care database were analyzed. Patients aged
C18 years, diagnosed with T2DM, and pre-
scribed liraglutide or lixisenatide between 01
May 2013 and 31 December 2015 were included
in the study. Adjusted linear regression models
compared the difference in mean change in
HbA1c, body mass index (BMI), and systolic
blood pressure (SBP) after 12-month follow-up.
The proportion of patients achieving glycemic
control (HbA1c\6.5%,\7.0%,\7.5%); HbA1c
reduction [1%; and weight reduction C3%
within 12 months were determined. Cox pro-
portional hazards modeling was used to evalu-
ate the effect of treatment on time to achieving
HbA1c and weight reduction targets. Healthcare
resource use (HCRU) (GP, secondary care, hos-
pitalizations) was compared using analysis of
covariance.
Results: The primary outcome was assessed in
579 liraglutide and 213 lixisenatide new users.
Fully adjusted linear regression indicated that
liraglutide reduced HbA1c significantly more
than lixisenatide (mean treatment difference
-0.30; 95% CI -0.56, -0.04; p = 0.025). Com-
pared to lixisenatide, liraglutide recipients were
2.5 times more likely to achieve HbA1c\6.5%
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(p = 0.0002). Liraglutide users were also more
likely to achieve HbA1c \7.0% (HR 2.10;
p\0.0001),\7.5% (HR 1.65; p\0.0001), and
[1% HbA1c reduction (HR 1.29; p = 0.0002).
BMI and SBP reductions were greater for the
liraglutide group but results were not signifi-
cant. HCRU was comparable between treatment
groups.
Conclusion: These results from the THIN data-
base indicate that liraglutide treatment pro-
vided better outcomes related to glycemic
control.
Funding: Novo Nordisk.
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INTRODUCTION
In the management of type 2 diabetes mellitus
(T2DM), the National Institute for Health and
Care Excellence (NICE) guidelines in the UK
recommend a patient-centered approach to
achieving and maintaining glycemic control by
individualizing target glycated hemoglobin
(HbA1c) levels [1]. Although glycemic control is
considered on a case-by-case basis, an HbA1c
target of 6.5% (48 mmol/mol) is recommended
for most patients with T2DM. Following drug
intensification, a secondary target of 7.0%
(53 mmol/mol) is suggested and 7.5%
(58 mmol/mol) is considered the threshold for
further drug escalation [2].
Glucagon-like peptide-1 receptor agonists
(GLP-1 RAs) are currently recommended as
third-line treatment in diabetes management in
UK clinical practice [2]. Liraglutide once daily
(Victoza, Novo Nordisk, Bagsvaerd, Denmark)
and lixisenatide once daily (Lyxumia,
Sanofi-Aventis Groupe, Paris, France) are two
GLP-1 RAs that have demonstrated clinical
efficacy in patients with T2DM in numerous
clinical studies [3–7]. Liraglutide was approved
in the EU in 2009 and lixisenatide gained
approval in 2013. Liraglutide and lixisenatide
(as add-on to metformin) have been compared
in randomized, open-label, parallel group trials
[4, 6], where liraglutide was more effective than
lixisenatide in improving glycemic control [6].
However, to our knowledge, no studies have
compared the effectiveness of liraglutide to
lixisenatide in patients treated in real-world
clinical practice.
This study aimed to assess the effectiveness
of liraglutide in comparison to lixisenatide in
adult T2DM patients treated in UK primary care
by using The Health Improvement Network
(THIN) database. Effectiveness was determined
by assessing the effects of these treatments on
HbA1c levels, body mass index (BMI), and sys-
tolic blood pressure (SBP) during the 12 months
following initiation of therapy. Healthcare
resource utilization (GP, secondary care, and
hospitalizations) between users of liraglutide
versus lixisenatide was also investigated.
METHODS
Study Design and Data Source
This observational study of adults with T2DM
utilized electronic medical record (EMR) data
from the THIN database, a large UK primary care
data source. THIN contains anonymizedmedical
records for over 13 million patients, of which
over 3.5 million are currently active, represent-
ing nearly 6%of theUK population. Studies have
demonstrated the validity of THINdata for use in
pharmacoepidemiological studies [8–10] and its
generalizability to the UK in terms of demo-
graphics and diabetes prevalence [11].
The period of observation was from 01 May
2013 (to coincide with licensing of lixisenatide
in the UK) to 31 December 2015. The index date
was the first recorded prescription issued for
liraglutide or lixisenatide within the study per-
iod as identified by relevant drug codes within
THIN. Clinical effectiveness was assessed from
index date to 12 months follow-up. Baseline
HbA1c, SBP, body weight, and BMI measure-
ments within the 6 months prior to index date
were included to reflect the UK National Insti-
tute of Health and Care Excellence (NICE) rec-
ommendation of HbA1c measurements every
3–6 months [2]. Similarly, 12-month follow-up
measurements were assessed at the 12-month
follow-up date ±3 months. Healthcare resource
418 Diabetes Ther (2017) 8:417–431
use was assessed from index date to 12 months
post-index. The study was reviewed and
approved by the UK Independent Scientific
Review Committee (SRC) under protocol
16THIN050. The analysis does not contain any
new studies with human or animal subjects
performed by any of the authors.
Study Population
Patients were eligible for inclusion in the study
population if they fulfilled all of the following
criteria: (i) at least one new prescription of
liraglutide or lixisenatide between 01 May 2013
and 31 December 2015, (ii) a recorded diagnosis
of T2DM at any time prior to or on index (based
on Read codes), (iii) C18 years at index, and (iv)
a minimum of 6 months of medical history
pre-index. Exclusion criteria were (i) diagnosis
of type 1 diabetes mellitus at any time, (ii)
record of gestational diabetes within 12 months
of index date, (iii) first prescription for liraglu-
tide prior to 01 May 2013, (iv) insulin pre-
scription prior to index, or (v) history of
malignancy prior to index date. Patients were
followed from liraglutide/lixisenatide initiation
(index date) until the earliest of (i) record of
insulin prescription, (ii) transfer out of practice/
death, or (iii) end of the study time period.
Cohorts were constructed from the main study
population for each outcome of interest on the
basis of availability of follow-up measurements
in order to maximize the populations available
for assessment.
Treatment Groups
Liraglutide prescriptions were categorized as the
following: all doses (any exposure to all avail-
able prescribed doses [0.6 mg, 1.2 mg, 1.8 mg
per day] during the study period); 1.2 mg cate-
gory, average daily dose (ADD) 0.6–1.5 mg; and
liraglutide 1.8 mg category, ADD [1.5–2.1 mg
[12]. ADD was calculated as the sum of the
prescribed number of units (pens) multiplied by
the total dosage in each unit (mg), divided by
the sum of the days covered by the prescrip-
tions. For lixisenatide, the standard 20 lg dose
per day was used.
RESULTS
Cohort Sizes and Baseline Characteristics
The primary outcome was the absolute change
in HbA1c at 12 months from index date. Sec-
ondary endpoints included (i) change in BMI
and SBP at 12 months from index (Fig. 1a). Of
the 1736 liraglutide users, 914 (52.6%) were
prescribed an average dose of 1.2 mg, 93 (5.4%)
were prescribed an average dose of 1.8 mg, and
for 729 (42.0%) patients the dose was unspeci-
fied. On the basis of availability of outcome
measurements, cohort 1 for both liraglutide and
lixisenatide treatment groups was divided into
five cohorts for each outcome of interest as
outlined in Fig. 1a, with cohorts 2 and 3 subdi-
vided into a further three categories according
to baseline HbA1c (Fig. 1b).
For the baseline cohort (cohort 1), the mean
age of patients in the lixisenatide group
(57.2 years, SD 10.7) was slightly greater than
those in the liraglutide group (55.8 years, SD
10.7). Mean weight and BMI were comparable
for both treatment groups (107.0 kg, SD 20.7;
37.6 kg/m2, SD 6.6 for lixisenatide vs. 109.9 kg,
SD 22.5; 38.1 kg/m2, SD 7.2 for liraglutide);
however, almost 30% of all patients had missing
weight data. Mean HbA1c levels at baseline were
high in both treatment groups but slightly
higher in patients prescribed lixisenatide
(9.64%, SD 1.53 lixisenatide vs. 9.49%, SD 1.63
liraglutide). Mean baseline SBP was also ele-
vated but comparable between cohorts
(133 mmHg, SD 14 for lixisenatide vs.
134 mmHg, SD 15 for liraglutide) (Table 1).
Treatment Effects
Unadjusted analyses demonstrated reductions
in absolute change in HbA1c after 12 months
for both liraglutide and lixisenatide initiators in
cohort 2 (Fig. 2), with greater reductions
observed in the liraglutide group (-0.93%
liraglutide vs. -0.70% lixisenatide) (Fig. 2a).
Using the change in estimate approach, no
variables altered the treatment coefficient by
more than 10%, but all were entered into the
fully adjusted model as a sensitivity analysis
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(Table 2). The fully adjusted linear regression
model for mean HbA1c change confirmed a
greater mean change in HbA1c for the liraglu-
tide group compared with the lixisenatide
group (-0.30, 95% CI -0.56 to -0.04,
p = 0.025). Linear regression analyses adjusted
only for baseline HbA1c (i.e., the baseline or
null model) demonstrated a similar result
(-0.28, 95% CI -0.54 to -0.02, p = 0.038). The
magnitude of the coefficient for the sensitivity
analyses using a mixed linear regression model
was very similar to the null model (-0.27, 95%
CI -0.55 to 0.01, p = 0.058), suggesting that
clustering of patients within practice did not
affect the model.
A greater proportion of the liraglutide group
compared to the lixisenatide group in cohort 3
achieved glycemic control targets of HbA1c
\6.5% (10.8% vs. 4.0%), \7.0% (24.1% vs.
11.7%), \7.5% (36.0% vs. 23.3%) (Fig. 3), and
Fig. 1 a THIN study cohort analysis diagram for main
baseline study population (cohort 1) and cohorts for each
outcome of interest according to availability of follow-up
measurements. b Subdivision of cohorts 2 and 3 into
categories according to baseline HbA1c. HbA1c glycated
hemoglobin, SBP systolic blood pressure
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Table 1 Baseline characteristics of patients prescribed liraglutide (all doses [0.6 mg, 1.2 mg, and 1.8 mg per day], and
separately for 1.2 mg and 1.8 mg per day) or lixisenatide (20 lg per day)
Liraglutide Lixisenatide
All doses (N5 1736) 1.2 mg (N5 914) 1.8 mg (N5 93) 20 lg (N5 578)
Age (years)
Mean (SD) 55.8 (10.7) 55.8 (10.3) 55.3 (10.7) 57.2 (10.7)
Unknown/missing (%) 0 0 0 0
Sex, n (%)
Male 951 (54.8) 511 (55.9) 57 (61.3) 295 (51.0)
Female 785 (45.2) 403 (44.1) 36 (38.7) 283 (49.0)
Unknown/missing (%) 0 0 0 0
Smoking status, n (%)a
Current 216 (12.4) 106 (11.6) 6 (6.5) 91 (15.7)
Former 539 (31.0) 266 (29.1) 35 (37.6) 190 (32.9)
Never 612 (35.3) 330 (36.1) 32 (34.4) 207 (35.8)
Unknown/missing (%) 369 (21.3) 212 (23.2) 20 (21.5) 90 (15.6)
Weight (kg)
Mean (SD) 109.9 (22.5) 110.4 (21.1) 109.3 (24.3) 107.0 (20.7)
Unknown/missing (%) 530 (30.5) 287 (31.4) 31 (33.3) 153 (26.5)
Height (m)
Mean (SD) 1.69 (0.10) 1.69 (0.10) 1.69 (0.10) 1.69 (0.10)
Unknown/missing (%) 1166 (67.2) 649 (71.0) 61 (65.6) 380 (65.7)
BMI (kg/m2)
Mean (SD) 38.1 (7.2) 38.2 (7.1) 37.1 (7.9) 37.6 (6.6)
Unknown/missing (%) 533 (30.7) 289 (31.6) 31 (33.3) 154 (26.6)
HbA1c (%)
Mean (SD) 9.49 (1.63) 9.49 (1.54) 9.66 (1.71) 9.64 (1.53)
Unknown/missing (%) 218 (12.6) 125 (13.7) 10 (10.8) 44 (7.6)
Systolic blood pressure (mmHg)
Mean (SD) 134 (15) 134 (15) 133 (15) 133 (14)
Unknown/missing (%) 425 (24.5) 225 (24.6) 28 (30.1) 136 (23.5)
Duration of diabetes (years)
Mean (SD) 8.1 (4.9) 8.0 (4.7) 8.6 (4.9) 8.3 (4.8)
Unknown/missing (%) 0 0 0 0
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[1% HbA1c reduction (76.0% vs. 63.6%)
(Fig. 4). When stratified by diabetes duration,
fewer patients tended to achieve each HbA1c
target as duration increased (Table 3). Cox
regression analysis adjusted for baseline HbA1c
revealed that, compared to the lixisenatide
group, patients in the liraglutide group were 2.5
times more likely to achieve HbA1c\6.5% and
approximately twice as likely to achieve HbA1c
\7.0% and \7.5% within 12 months of treat-
ment (Table 4). Patients in the liraglutide group
were statistically more likely to achieve [1%
reduction in HbA1c compared to patients in the
lixisenatide group (Table 4).
Unadjusted analyses indicated slightly
greater BMI and SBP reductions for liraglutide
users compared to lixisenatide users (cohort 5
and 6; Fig. 2b, c). However, there was no sig-
nificant difference in mean change in BMI and
SBP between treatment groups (linear regression
adjusted for baseline BMI and baseline SBP,
respectively) (Table 2). A slightly greater pro-
portion of the liraglutide group (44.9%)
achieved C3% reduction in weight compared
with the lixisenatide group (40.8%) (cohort 5;
Fig. 4). Cox regression analysis adjusted for
baseline weight indicated that patients in the
liraglutide group were more likely to achieve
C3% reduction in weight within 12 months
compared to the lixisenatide group; however,
this difference was not statistically significant
(Table 4).
The overall number of GP visits recorded
within a year from index date was the same for
the two groups. Similar trends were seen for
face-to-face visits, nurse visits, and phone calls
to the GP (Table 5). There were no differences
between the groups regarding the mean number
of secondary care visits or hospitalizations in
the year after index date (Table 5). ANCOVA
with adjustment for baseline HbA1c and length
of time at risk revealed no significant differences
between the two treatment groups.
DISCUSSION
This real-world observational study indicated
that liraglutide-treated individuals experienced
Table 1 continued
Liraglutide Lixisenatide
All doses (N5 1736) 1.2 mg (N5 914) 1.8 mg (N5 93) 20 lg (N5 578)
Comorbid disease history, n (%)
Cardiovascular disease 97 (5.6) 40 (4.4) b 30 (5.2)
Hepatic disease 24 (1.4) 11 (1.2) b 14 (2.4)
Urinary tract infections 65 (3.7) 25 (2.7) b 28 (4.8)
Baseline concomitant diabetes medication, n (%)
Monotherapy 683 (39.3) – – 203 (35.1)
Dual therapy 806 (46.4) – – 299 (51.7)
Triple therapy 225 (13.0) – – 70 (12.1)
BMI body mass index, HbA1c glycated hemoglobin, SD standard deviation
a Percentages were based on patients with available data
b Small number suppression applied for patient numbers\6
Fig. 2 12-Month treatment effects of liraglutide (all doses
[0.6 mg, 1.2 mg, and 1.8 mg per day] and separately for 1.2
and 1.8 mg per day, or lixisenatide (20 lg per day) with
respect to a HbA1c (cohort 2) b body mass index (cohort
5), and c systolic blood pressure (cohort 6). Mean values
were calculated for patients with available data. BMI body
mass index, HbA1c glycated hemoglobin, SBP systolic
blood pressure
c
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Table 2 Linear regression analyses of mean change in HbA1c, BMI, and SBP from baseline to 12 months in patients
prescribed liraglutide (all doses [0.6 mg, 1.2 mg, and 1.8 mg per day], and separately for 1.2 mg and 1.8 mg per day) versus
lixisenatide (20 lg per day)
Linear regression analyses
b 95% LCL 95% UCL p value
Mean change in HbA1c: baseline modela
Lixisenatide (20 lg) –
Liraglutide (all doses) -0.278 -0.541 -0.016 0.038
Liraglutide (1.2 mg) -0.362 -0.633 -0.092 0.009
Liraglutide (1.8 mg) -0.417 -0.965 0.130 0.135
Mean change in HbA1c: fully adjusted modelb
Lixisenatide (20 lg) –
Liraglutide (all doses) -0.297 -0.556 -0.037 0.025
Liraglutide (1.2 mg) -0.395 -0.663 -0.128 0.004
Liraglutide (1.8 mg) -0.502 -1.040 0.036 0.068
Mean change in BMI: baseline modelc
Lixisenatide (20 lg) –
Liraglutide (all doses) -0.009 -0.488 0.469 0.969
Liraglutide (1.2 mg) -0.005 -0.526 0.516 0.985
Liraglutide (1.8 mg) -0.076 -1.177 1.026 0.893
Mean change in SBP: baseline modeld
Lixisenatide (20 lg) –
Liraglutide (all doses) -0.404 -2.644 1.837 0.724
Liraglutide (1.2 mg) -0.851 -3.082 1.381 0.454
Liraglutide (1.8 mg) -0.171 -4.741 4.399 0.941
b b-coefﬁcient, BMI body mass index, HbA1c glycated hemoglobin, LCL lower conﬁdence limit, SBP systolic blood
pressure, UCL upper conﬁdence limit
a Linear regression adjusted for treatment and baseline HbA1c only. N = 784 for the model with all doses of liraglutide and
N = 649 for the model with doses split into 1.2 and 1.8 mg
b Linear regression adjusted for all covariates (for baseline HbA1c, age, gender, smoking status, history of hepatic disease,
history of urinary tract infection, concomitant medication, history of cardiovascular disease, and diabetes duration). BMI
was not adjusted for because of a high level of missing values and an assumed assumption of causal linkage between exposure
and outcome. N = 784 for the model with all doses of liraglutide and N = 649 for the model with doses split into 1.2 and
1.8 mg
c Linear regression adjusted for treatment and baseline BMI only. N = 569 for the model with all doses of liraglutide and
N = 478 for the model with doses split into 1.2 and 1.8 mg
d Linear regression adjusted for treatment and baseline SBP only. N = 666 for the model with all doses of liraglutide and
N = 559 for the model with doses split into 1.2 and 1.8 mg
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greater reductions in HbA1c than lixisen-
atide-treated individuals during the 12 months
following treatment initiation. Additionally, a
greater proportion of patients initiating
liraglutide achieved HbA1c targets compared to
lixisenatide patients. These findings from
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Fig. 3 Proportion of patients in cohort 2 achieving
HbA1c levels \6.5%, \7.0%, and \7.5% within
12 months of therapy with liraglutide (all doses [0.6 mg,
1.2 mg, and 1.8 mg per day] and separately for 1.2 mg and
1.8 mg per day) or lixisenatide (20 lg per day). Propor-
tions were calculated on the basis of patients with available
data. HbA1c glycated hemoglobin
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Fig. 4 Proportion of patients achieving [1% HbA1c
reduction (cohort 3) and C3.0% reduction in weight
(cohort 4) within 12 months of therapy initiation with
liraglutide (all doses [0.6 mg, 1.2 mg, and 1.8 mg per day],
and separately for 1.2 mg and 1.8 mg per day) or
lixisenatide (20 lg per day). Proportions were calculated
on the basis of patients with available data. HbA1c glycated
hemoglobin
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real-world clinical practice are aligned with
results from head-to head randomized con-
trolled trials (RCT) where patients in liraglutide
treatment groups demonstrated greater reduc-
tions in HbA1c levels than patients in lixisen-
atide treatment groups [4–6].
Baseline clinical characteristics were similar
between treatment groups. Approximately three
times more patients were prescribed liraglutide
compared to lixisenatide, which may be due to
longer market availability and thus increased
familiarity with liraglutide. Importantly, the
present study found that patients prescribed
liraglutide or lixisenatide had higher mean
baseline HbA1c levels compared to patients in
RCTs, but this could be influenced by inclusion
criteria thresholds for RCTs [4–6]. In clinical
practice, high mean HbA1c could be explained
by current UK NICE guidelines recommending
GLP-1 RA as a third-line treatment option in
Table 3 Proportion of patients prescribed liraglutide (all doses [0.6 mg, 1.2 mg, and 1.8 mg per day], and separately for
1.2 mg and 1.8 mg per day) or lixisenatide (20 lg per day) achieving HbA1c and weight reduction targets within 12 months
of therapy, stratiﬁed by diabetes duration
Liraglutide Lixisenatide
All doses
% (n/N)
1.2 mg
% (n/N)
1.8 mg
% (n/N)
20 lg
% (n/N)
HbA1c target\6.5%
Diabetes duration\5 years 16.9 (63/372) 21.1 (47/223) a 11.2 (14/125)
Diabetes duration 5–10 years 9.9 (43/436) 13.6 (38/279) a a
Diabetes duration[10 years 6.2 (25/405) 7.2 (17/235) a a
HbA1c target\7.0%
Diabetes duration\5 years 30.6 (110/360) 37.9 (83/219) 33.3 (7/21) 22.8 (28/123)
Diabetes duration 5–10 years 23.7 (102/431) 29.8 (82/275) 25.9 (7/27) 9.7 (16/165)
Diabetes duration[10 years 18.7 (74/395) 24.6 (57/232) 22.2 (6/27) 5.1 (8/158)
HbA1c target\7.5%
Diabetes duration\5 years 45.5 (151/332) 55.3 (114/206) 38.9 (7/18) 34.5 (41/119)
Diabetes duration 5–10 years 34.1 (143/419) 43.1 (116/269) 40.7 (11/27) 22.6 (37/164)
Diabetes duration[10 years 29.8 (114/383) 38.3 (87/227) 34.6 (9/26) 15.5 (24/155)
[1% HbA1c reduction
Diabetes duration\5 years 78.8 (298/378) 86.8 (197/227) 81.8 (18/22) 64.3 (81/126)
Diabetes duration 5–10 years 74.9 (331/442) 85.9 (244/284) 85.2 (23/27) 64.0 (110/172)
Diabetes duration[10 years 74.7 (307/411) 82.9 (198/239) 67.9 (19/28) 62.7 (101/161)
C3% weight reduction
Diabetes duration\5 years 49.0 (51/104) 58.7 (37/63) a 51.6 (16/31)
Diabetes duration 5–10 years 37.6 (38/101) 45.2 (28/62) a 40.8 (20/49)
Diabetes duration[10 years 47.7 (51/107) 54.2 (32/59) 54.6 (6/11) 32.5 (13/40)
HbA1c glycated hemoglobin
a Small number suppression applied for patient numbers\6
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patients for whom triple therapy with met-
formin and two other oral drugs was either not
effective, not tolerated, or contraindicated [2].
When assessing the primary outcome,
notable differences between the treatment
groups were observed for patients with
12 months of available data where patients ini-
tiating liraglutide achieved a significantly
greater reduction in HbA1c than those initiated
on lixisenatide. This supports previous head-
to-head RCTs where liraglutide demonstrated
superior reductions in HbA1c levels compared
with lixisenatide in 26-week [6], 28-day [4], and
8-week RCTs [5].
Additionally, results from an observational
study suggest that the observed greater mean
reduction in HbA1c may be regarded as clinically
relevant [13]. The findings indicated that reduc-
ing HbA1c by 1% may reduce the risk of dia-
betes-related death by 21% and all-cause
mortality by 14%. These results, however, could
not be reproduced in the three major glu-
cose-lowering trials ADVANCE, ACCORD, and
VADT [14–16].More recently,meta-analyses have
found that reducing HbA1c could significantly
reduce the incidence of non-fatal myocardial
infarction and coronary heart disease, although
this is less certain for all-cause mortality [17, 18].
Approximately three-quarters of the liraglu-
tide group and two-thirds of the lixisenatide
group achieved[1% reduction in HbA1c. These
proportions were greater than observed in two
Table 4 Cox proportional hazards (PH) regression analyses for liraglutide (all doses [0.6 mg, 1.2 mg, and 1.8 mg per day])
versus lixisenatide (20 lg per day) to assess the effect of exposure on time to achieving HbA1c and weight reduction targets
within 12 months of therapy
Cox PH regression analyses
HR 95% LCL 95% UCL p value
Probability of achieving HbA1c\6.5%a
Lixisenatide (20 lg) (N = 454) –
Liraglutide (all doses) (N = 1213) 2.54 1.55 4.16 0.0002
Probability of achieving HbA1c\7.0%a
Lixisenatide (20 lg) (N = 446) –
Liraglutide (all doses) (N = 1186) 2.10 1.57 2.83 \0.0001
Probability of achieving HbA1c\7.5%a
Lixisenatide (20 lg) (N = 438) –
Liraglutide (all doses) (N = 1134) 1.65 1.33 2.05 \0.0001
Probability of achieving[1% HbA1c reductiona
Lixisenatide (20 lg) (N = 459) –
Liraglutide (all doses) (N = 1231) 1.29 1.13 1.47 0.0002
Probability of achieving C3% weight reductionb
Lixisenatide (20 lg) (N = 120) –
Liraglutide (all doses) (N = 312) 1.12 0.82 1.53 0.493
HbA1c glycated hemoglobin, HR hazard ratio, LCL lower conﬁdence limit, PH proportional hazards, UCL upper conﬁ-
dence limit
a Cox PH regression adjusted for baseline HbA1c only
b Cox PH regression adjusted for baseline weight only
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other real-world liraglutide studies, where just
over half of liraglutide users achieved C1%
HbA1c reduction after 6 months of treatment
[19, 20]. Furthermore, patients initiated on
liraglutide had a statistically significant higher
probability than lixisenatide users of achieving
glycemic targets (including \6.5%) over
12 months. We found that glycemic control
targets were attained by a greater proportion of
the liraglutide group versus the lixisenatide
group. This largely agrees with RCT and real--
world data, although the relative proportions of
patients achieving these targets were lower than
in clinical trials examining liraglutide 1.8 mg
[6, 21]. These lower proportions could be
explained by the high mean baseline HbA1c in
Table 5 GP, secondary care visits, and hospitalizations of liraglutide users (all doses [0.6 mg, 1.2 mg, and 1.8 mg]) and
lixisenatide users during 12 months following initiation of treatment
All patients Liraglutide Lixisenatide
All GP visits
Number of patients 2247 1681 566
Mean (SD) 9.8 (7.5) 9.7 (7.5) 9.8 (7.4)
Median (IQR) 8.0 (5.0, 13.0) 8.0 (5.0, 13.0) 8.0 (5.0, 13.0)
Face-to-face GP visits
Number of patients 2201 1646 555
Mean (SD) 7.2 (5.6) 7.2 (5.6) 7.2 (5.4)
Median (IQR) 6.0 (3.0, 10.0) 6.0 (3.0, 10.0) 6.0 (3.0, 9.0)
GP nurse visits
Number of patients 1154 865 289
Mean (SD) 3.0 (3.0) 3.0 (2.8) 3.1 (3.3)
Median (IQR) 2.0 (1.0, 4.0) 2.0 (1.0, 4.0) 2.0 (1.0, 4.0)
GP calls
Number of patients 1096 803 293
Mean (SD) 2.4 (2.3) 2.4 (2.3) 2.4 (2.4)
Median (IQR) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0)
Secondary care visits
Number of patients 1687 1261 426
Mean (SD) 2.4 (1.4) 2.4 (1.5) 2.4 (1.4)
Median (IQR) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0)
Hospitalizations
Number of patients 458 346 112
Mean (SD) 1.3 (0.7) 1.3 (0.7) 1.3 (0.6)
Median (IQR) 1.0 (1.0, 1.0) 1.0 (1.0, 1.0) 1.0 (1.0, 1.0)
IQR interquartile range, SD standard deviation
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our study, which has previously been identified
as a significant predictor of achieving HbA1c
targets in response to liraglutide [22]. Response
may also be influenced by duration of diabetes;
our results indicated a poorer response to the
glycemic reduction and control targets with
increased duration, a finding consistent with
the Association of British Clinical Diabetologists
Nationwide Liraglutide Audit [23].
Despite greater improvement in glycemic
control with liraglutide use, both liraglutide
and lixisenatide use was associated with a sim-
ilar number of GP, secondary care, and hospital
visits in the year following index. Results from a
long-term clinical trial have suggested that
treatment with liraglutide could be associated
with reduced resource use due to a reduction in
microvascular and macrovascular events [24].
Our study supports the findings of RCTs and
observational studies but carries potential limi-
tations. For some outcomes (i.e., HbA1c,
weight), data were not available at both baseline
and 12-month follow-up, which could lead to
selection bias. However, time windows for
measurements were decided according to
guidelines for measurement frequency [2] in
order to maximize the number of patients in the
study. Confounding by indication (i.e., indica-
tion bias) resulting from differences in reasons
for prescription may lead to systematic bias in
favor or against liraglutide. Indication bias may
be limited since both liraglutide and lixisen-
atide belong to the same drug class and both are
used as a third-line treatment in the UK. How-
ever, the longer market availability and thus
familiarity of liraglutide may result in it being
preferentially prescribed, as was reflected in the
greater number of patients prescribed liraglu-
tide. Multiple linear regression models were
applied to mitigate any possible limitations in
terms of confounding. The current study was
also limited by data contained within the THIN
database. Firstly, medication data are based on
prescriptions issued rather than prescriptions
dispensed and thus it was not possible to con-
firm that the drug was actually taken by the
patient. Secondly, GPs in England received
incentives during the study time period for
reporting diabetes, while GPs in Wales, North-
ern Ireland, and Scotland did not. This may
have led to an oversampling of patients from
English GPs and a higher quality of recording
compared to GPs from Wales, Northern Ireland,
and Scotland.
CONCLUSIONS
These data from UK clinical practice provide
real-world evidence that liraglutide compared
to lixisenatide is associated with greater reduc-
tions in HbA1c and a greater likelihood of
achieving HbA1c targets, supporting the results
from previous clinical trials.
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